SCHEMBL24124184

SCHEMBL24124184

CN(Cc1ccc(NC(=O)c2ccc3c(c2)CCCS3)cc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 3/20 0.47
▸ HDAC3 O15379 2/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ NCOR2 Q9Y618 1/20 0.47
▸ MCHR1 Q99705 1/20 0.44
▸ RXRA P19793 1/20 0.44
▸ RXRB P28702 1/20 0.44
▸ RXRG P48443 1/20 0.44
▸ MAPT P10636 7/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ TNF P01375 2/20 0.40
▸ NOD2 Q9HC29 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24124181 0.90 PTGES (0.44) HDAC1HDAC3HDAC2NCOR2MCHR1
SCHEMBL25921185 0.82 MAPT (0.46) HDAC1HDAC3HDAC2NCOR2MAPT
SCHEMBL25921521 0.82 MAPT (0.61) MAPTSMN1; SMN2ALDH1A1LMNAKMT2A
SCHEMBL24124737 0.81 MAPT (0.40) NCOR2MAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL8460319 0.80 MEN1 (0.52) NCOR2MAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL24124916 0.79 MAPT (0.52) MAPTSMN1; SMN2TP53ALDH1A1LMNA
SCHEMBL24124746 0.79 MAPT (0.41) NCOR2MAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL9147195 0.79 MEN1 (0.51) NCOR2MAPTSMN1; SMN2TP53ALDH1A1
SCHEMBL24125182 0.77 ALDH1A1 (0.55) HDAC1HDAC3HDAC2NCOR2MAPT
SCHEMBL25924692 0.77 HDAC1 (0.66) HDAC1HDAC3HDAC2NCOR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 HDAC1 898/4885HDAC3 1997/4885HDAC2 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback